Improving sleep and cognition in children with Down syndrome using medications.
Medications for Obstructive Sleep Apnea to Improve Cognition in Children with Down Syndrome (MOSAIC DS)
This study is looking at whether a mix of two medications, atomoxetine and oxybutynin, can help kids with Down syndrome who have obstructive sleep apnea sleep better and think more clearly.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project ID | NIH-10909897 on NIH RePORTER |
What this research studies
This research investigates the use of a combination of medications, atomoxetine and oxybutynin, to treat obstructive sleep apnea (OSA) in children with Down syndrome. OSA is common in these children and can lead to cognitive impairments and reduced quality of life. The study aims to determine if this medication combination can improve airway tone during sleep, thereby alleviating OSA symptoms and enhancing cognitive function. By focusing on a well-tolerated treatment option, the research seeks to provide a viable alternative to current therapies that may not be effective for all patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are children with Down syndrome who are diagnosed with obstructive sleep apnea.
Not a fit: Patients without Down syndrome or those who do not have obstructive sleep apnea may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve cognitive function and quality of life for children with Down syndrome suffering from obstructive sleep apnea.
How similar studies have performed: Previous research has shown that similar approaches using hypoglossal nerve stimulation have been effective in adolescents with Down syndrome, indicating potential for success with this medication-based approach.
Where this research is happening
Tucson, United States
- University of Arizona — Tucson, United States (Active)
Researchers
- Principal investigator: Combs, Daniel — University of Arizona
- Study coordinator: Combs, Daniel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.